UNSPSC 51142433: Rizatriptan benzoate

This classification denotes a serotonin agonist with the molecular formula C15H19N5.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WR978S7QHH, chemically known as 1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)- but more generally known as rizatriptan benzoate, which bears US NIH Compound Identifier 5078. European Medicines Agency schedules Rizatriptan benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04258MIG.

Most nations, for tariff and trade purposes, schedule rizatriptan benzoate under HS 29339990 and SITC 51577. As of Q4 2014, RIZATRIPTAN BENZOATE remains US FDA's Preferred Term for this commodity. Rizatriptan benzoate bears US NLM identifiers UMLS ID C0772420 and NCI Concept Code C47708. SMILES: CN(C)CCC1C[NH]C2C1CC(CC2)CN3CNCN3.C1CCC(CC1)C(=O)O.

UNSPSC 51142433 Rizatriptan benzoate, a Commodity code, nominally covers a specific migraine medication, but recent state and local procurement activity under this code does not reflect purchases of rizatriptan or other brand-specific pharmaceuticals. Instead, the opportunities posted under this code target broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program development. State and local buyers using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and participating jurisdictions). The scope reflects community health and pharmacy benefit management rather than single-drug acquisitions, with vendors expected to supply through authorized wholesalers, maintain cGMP and DSCSA compliance, carry substantial liability insurance, and manage quarterly or ongoing deliveries to multiple locations.

Recent activity appears concentrated in the South and Upper Midwest. Seminole County posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2023 (note: the source date appears to contain an inconsistency). Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription contracting capabilities as preliminary market intelligence prior to formal procurement. Minnesota's MMCAP posted an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and performance evaluated 75 percent on price competitiveness. The code's actual activity does not align closely with its nominal scope, suggesting either inconsistent tagging by issuing bodies or a mismatch between the UNSPSC classification and the work being procured.